FGFR2 and neoplasm: CNVs in tumour cells also enhance proliferation, albeit at the expense of the host; for example, copy number amplification can drive tumour growth (e.g., of FGFR2 or CDK4 [13, 14]) or mediate drug resistance (e.g., of DHFR, KRAS or BRAF [15–17]).